Reneo Pharmaceuticals, Inc. (RPHM)

Market Cap	58.63M
Revenue (ttm)	n/a
Net Income (ttm)	-77.39M
Shares Out	33.31M
EPS (ttm)	-2.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	73,919
Open	1.780
Previous Close	1.770
Day's Range	1.700 - 1.780
52-Week Range	0.980 - 11.295
Beta	0.24
Analysts	Buy
Price Target	11.46 (+551.14%)
Earnings Date	May 9, 2024

About RPHM

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquarte...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 9, 2021
• Employees: 8
• Stock Exchange: NASDAQ
• Ticker Symbol: RPHM

Analyst Forecast

According to 6 analysts, the average rating for RPHM stock is "Buy." The 12-month stock price forecast is $11.46, which is an increase of 551.14% from the latest price.

Price Target

$11.46

(551.14% upside)

Analyst Consensus: Buy